On October 10, 2025, Autonomix Medical, Inc. announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,369,852, titled “Controlled and Precise Treatment of Cardiac Tissues.” The patent was granted today and adds a critical intellectual‑property asset to the company’s portfolio.
The newly issued patent covers a suite of systems, devices, and methods that sense autonomic and cardiac signals, map target tissues, and deliver therapy with closed‑loop feedback. It enables precise neuromodulation, denervation, and/or ablation of cardiac tissues, providing a technology platform that can be applied to a range of cardiac conditions.
The patent’s scope includes applications in arrhythmias (atrial and ventricular), ischemia and refractory angina, coronary spasm, myocardial infarction risk modulation, heart failure, and hypertension, including renal‑cardiac nerve interactions. By addressing these high‑growth therapeutic areas, the patent expands Autonomix’s potential market beyond its initial focus on pancreatic cancer pain.
This milestone strengthens Autonomix’s IP position, supports future FDA submissions for cardiology indications, and positions the company to pursue revenue opportunities in multiple high‑need markets such as hypertension, arrhythmia management, and heart failure. The patent underscores the company’s strategy to leverage its catheter‑based sensing platform across diverse disease areas.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.